Introduction
============

Overactivation of the unfolded protein response (UPR) has emerged as a major pathogenic mechanism across the spectrum of neurodegenerative diseases, for which no disease-modifying treatments currently exist ([@awx074-B10]; [@awx074-B42]). Dysregulation of the pancreatic endoplasmic reticulum kinase (PERK) branch of the UPR is particularly prominent: high levels of activated PERK (PERK-P) and its downstream target, the phosphorylated alpha subunit of eukaryotic initiation factor 2 (eIF2&alpha;) are seen in brains of patients with Alzheimer&rsquo;s and Parkinson&rsquo;s diseases, progressive supranuclear palsy and frontotemporal dementia (FTD) ([@awx074-B11], [@awx074-B12]; [@awx074-B45]), and also in the rare prion disorders. In these disorders, PERK-P and eIF2&alpha;-P accumulation are temporally and spatially associated with the deposition of disease-specific misfolded proteins&mdash;notably phosphorylated tau in Alzheimer&rsquo;s disease and progressive supranuclear palsy ([@awx074-B29]; [@awx074-B45]). Figure 1**A screening approach uncovers two partial inhibitors of the UPR**. (**A**) Luciferase expression in CHOP::luciferase cells treated with tunicamycin (Tm) (3&thinsp;&mu;g/ml) and compounds from primary screen (grey bars) ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}), ISRIB (turquoise bar), GSK2606414 (green bar) or tunicamycin alone (black bar). &lsquo;Hits&rsquo;, including DBM (magenta bar) and trazodone (navy bar), repress luciferase expression to similar extent to ISRIB (dotted line). All drugs at 20&thinsp;&mu;M, except ISRIB, 1&thinsp;&mu;M; *n*&thinsp;&equals;&thinsp;3 and all experiments performed in triplicate. (**B**) DBM and trazodone inhibit luciferase expression in a dose-dependent manner. Concentrations of tunicamycin and GSK2606414 and *n* as in **A**.

eIF2&alpha;-P controls global protein synthesis rates by inhibiting translation at the level of initiation ([@awx074-B43]). Phosphorylation of eIF2&alpha; is controlled by activation of PERK, and also by the eIF2&alpha; kinases of the closely related integrated stress response (ISR) ([@awx074-B37]). In the brain, eIF2&alpha; represents a hub for controlling rates of protein synthesis essential for learning and memory formation and for maintaining neuronal integrity in health and disease. Sustained overactivation of PERK/eIF2&alpha;-P signalling causes chronic translational attenuation leading to synapse loss and neurodegeneration in prion-diseased and FTD mice ([@awx074-B27]; [@awx074-B33]). This is prevented by genetic and pharmacological interventions that reduce or inhibit eIF2&alpha;-P signalling, restoring translation rates ([@awx074-B27], [@awx074-B26]; [@awx074-B6]; [@awx074-B33]). Similar interventions restore memory in various mouse models of Alzheimer&rsquo;s disease ([@awx074-B20]; [@awx074-B2]) and boost memory in wild-type mice ([@awx074-B40]). This occurs downstream and irrespective of the disease-specific misfolded protein/s involved, with broad relevance for potential treatment of a range of neurodegenerative diseases. However, preclinical pharmacological approaches have not yet yielded compounds suitable for translation to the clinic. Despite being markedly neuroprotective, the selective PERK inhibitor, GSK2606414, is toxic to the pancreas due to the extent of UPR inhibition and on-target effects of PERK inhibition ([@awx074-B26]; [@awx074-B6]). In contrast, the small molecule ISRIB ([@awx074-B40]), which acts downstream of eIF2&alpha;-P ([@awx074-B39]; [@awx074-B41]), is neuroprotective without pancreatic toxicity, due to an inherent limitation in its potency for UPR/ISR inhibition ([@awx074-B6]). ISRIB, however, is highly insoluble and unsuitable for use in humans in its current form. Thus, despite the promise of the mechanistic target, safe and effective drugs acting on the pathway do not exist.

The development of such therapeutics is the focus of many drug discovery initiatives. However, this is in an inherently time-consuming and costly endeavour. In contrast, drug repurposing can bypass much of this process, if existing compounds with the desired activity can be found amongst the current pharmacopeia. Thus, in an effort to identify safe drugs with anti-eIF2&alpha;-P therapeutic activity, but lacking associated toxicity and/or adverse pharmacokinetic properties, we carried out phenotypic screens using the NINDS (National Institute for Neurological Disorders and Stroke) Custom Collection 2 Library of 1040 compounds containing &sim;75&percnt; FDA-approved drugs (often already licensed for use in patients). Our aim was to identify compounds that can reverse UPR/ISR activation induced by UPR stressors such as tunicamycin or thapsigargin in cells/model systems. This would allow detection of compounds with pharmacological activity on the UPR/ISR, which could be tested for therapeutic efficacy *in&nbsp;vivo.*

Our screens yielded two compounds with anti-eIF2&alpha;-P activity that we took forward to test in mouse models of neurodegeneration. Biochemically, trazodone hydrochloride, a licensed anti-depressant, and dibenzoylmethane (DBM) restored protein synthesis rates in prion-diseased and tauopathy FTD mice with established disease. Clinically, both drugs prevented the emergence of clinical signs in most treated prion-diseased mice and restored memory in FTD mice; pathologically, both drugs markedly reduced neuronal loss and hippocampal atrophy in both models. There was no toxicity, in particular to the pancreas. Given the prevalence of UPR activation in Alzheimer&rsquo;s disease, other tauopathies and related disorders, we propose that these compounds could be rapidly repositioned for clinical trials to determine the efficacy of this therapeutic approach for the treatment of dementia.

Materials and methods
=====================

Cell culture
------------

CHO-KI CHOP::luciferase cells (gift of David Ron) and Chinese hamster ovary (CHO) cells were cultured in Dulbecco&rsquo;s modified Eagle medium (DMEM)/F12(Ham) (Gibco) supplemented with 10&percnt; foetal calf serum, 2&thinsp;mM [l]{.smallcaps}-glutamine and 1&times; penicillin/streptomycin. HEK293 cells (Invitrogen), and mouse neuroblastoma N~2~A cells were cultured in DMEM (Gibco) supplemented with 10&percnt; foetal calf serum, 2&thinsp;mM [l]{.smallcaps}-glutamine and 1&times; penicillin/streptomycin. All cells were maintained at 37&deg;C with 5&percnt; CO~2~. Cell lines were chosen due to known robust UPR responses, and regularly checked for mycoplasma contamination.

CHOP::luciferase assay
----------------------

CHO-KI cells stably transfected with a CHOP::luciferase reporter ([@awx074-B7]) were plated at a density of 10^5^ per well in a 24-well plate and left to grow overnight. Cells were treated for 6&thinsp;h with 5&thinsp;&mu;g/ml tunicamycin or vehicle only \[100&percnt; dimethylsulphoxide (DMSO)\] and then extracted using the Steady-Glo&reg; luciferase assay system (Promega) before being quantified using the GloMax&reg; 96 microplate luminometer (Promega). The hits from the *Caenorhabditis elegans* screen ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}) were incubated with 5&thinsp;&mu;g/ml tunicamycin for 6&thinsp;h at 20&thinsp;&mu;M before assaying as above. Drugs that reduced CHOP::luciferase expression by &sim;50&percnt; (in a similar manner to ISRIB) ([@awx074-B6]) are predicted to be efficacious without toxicity.

Immunoblotting
--------------

Protein samples were isolated from hippocampi or cells using RIPA lysis buffer (150&thinsp;mM NaCl, 1&percnt; Triton^&trade;^ X-100, 0.5&percnt; sodium deoxycholate, 0.1&percnt; SDS and 50&thinsp;mM Tris pH8.0) supplemented with PhosSTOP^&trade;^ and protease inhibitors (Roche). Protein levels were determined by resolving 20&thinsp;&mu;g of protein on SDS-PAGE gels, transferred onto nitrocellulose or PVDF membranes and incubated with primary antibodies for eIF2&alpha;-P (1:1000; Cell Signaling 3597s), eIF2&alpha; (1:1000; Cell Signaling 2103s), ATF4 (CREB-2, 1:1000; Santa Cruz sc200), ATF6 (1:1000; Genetek 70B1413), GSK3&beta; (1:2000, Cell Signaling, 9832), pSer9-GSK3&beta; (1:1000, Cell Signaling, 9322), total tau (tau-5, 1:2000; Invitrogen ANB0042), p-tau (AT100, 1:2000; Thermo Fisher Scientific MN1060). Horseradish peroxidase-conjugated secondary antibodies (1:5000; Dako) were applied and protein visualized using enhanced chemiluminescence (GE Healthcare) and quantitated using ImageJ. Antibodies against GAPDH (1:5000; Santa Cruz sc32233), &beta;-actin (1:5000; Abcam ab8227) and &beta;-tubulin (1:5000; Millipore MAB1637) were used to determine loading. To detect PrP^Sc^ (prion protein) homogenized samples were digested with 50&thinsp;&mu;g/ml of proteinase K (PK) at 37&deg;C for 1&thinsp;h prior to electrophoresis. Membranes were then probed with ICSM-35 (1:10&thinsp;000; D-GEN 0130-03501) and goat anti-mouse (1:10&thinsp;000; Dako).

*XBP1* splicing assay
---------------------

Total RNA was extracted from CHO-KI cells with the mirVana^&trade;^ RNA/miRNA isolation kit (Ambion Inc.). RNA samples were reverse-transcribed with ImProm-II^&trade;^ reverse transcriptase (Promega) by priming with oligo(dT). *XBP1* (x-box binding protein 1) mRNA was amplified with primers flanking the 26 base pair intron (5&rsquo;-GGAGTGGAGTAAGGCTGGTG and 5&rsquo;-CCAGAATGCCCAAAAGGATA) with Phusion&reg; High-Fidelity Taq Polymerase (New England Biolabs). Polymerase chain reaction (PCR) products were resolved on 3&percnt; agarose gels. Mouse neuroblastoma cells (N~2~A) were treated with tunicamycin (5&thinsp;&mu;g/ml) for 8&thinsp;h and used as a positive control for *XBP1* splicing ([@awx074-B32]).

Quantification of *XBP1* splicing by quantitative PCR
-----------------------------------------------------

HEK293 cells were treated with tunicamycin (5&thinsp;&mu;g/ml) and either trazodone, DBM (both 20&thinsp;&mu;M) or DMSO for 6&thinsp;h. Total RNA was extracted with the mirVana^&trade;^ RNA/miRNA isolation kit (Ambion Inc.). RNA samples were reverse-transcribed with ImProm-II^&trade;^ reverse transcriptase (Promega) by priming with oligo(dT). Quantitative PCR was carried out at 95&deg;C for an initial 3&thinsp;min followed by 35 cycles of denaturation at 95&deg;C for 10&thinsp;s, annealing at 65&deg;C for 15&thinsp;s and extension at 72&deg;C for 30&thinsp;s using SYBR&reg; Green supermix and StepOnePlus^&trade;^ thermocycler (Applied Biosystems). Spliced *XBP1* was detected using primers: forward 5\'TGCTGAGTCCGCAGCAGGTG3\' and reverse 5\'GCTGGCAGGCTCTGGGGAAG3\' and compared to the &beta;-actin reference gene (forward 5&rsquo;CCGATCCACACGGAGTACTTG3&rsquo; and reverse 5&rsquo;GGCACCCAGCACAATGAAG3&rsquo;).

Puromycin labelling and immunoblot analysis
-------------------------------------------

The effects of endoplasmic reticulum stress on puromycinylated protein levels were determined as previously described ([@awx074-B6]). In brief, 10^6^ HEK293 cells were plated in 6-well plates. Two days later, culture media was changed to fresh media, and cells were treated with vehicle (DMSO) or thapsigargin in the presence or absence of the indicated concentration of inhibitors for 2.5&thinsp;h. For puromycin labelling, 10&thinsp;&mu;g/ml puromycin was added during the last 10&thinsp;min before harvest. Cells were lysed with passive lysis buffer (Sigma) supplemented with protease inhibitor cocktail (Roche). After centrifugation at 13&thinsp;000&thinsp;rpm for 20&thinsp;min, supernatants were mixed with SDS-PAGE sample buffer. To detect puromycinylated protein 20&thinsp;&mu;g of total protein, respectively, was subjected to 12&percnt; SDS-PAGE and transferred onto PVDF membrane. Immunoblot detection was conducted using primary antibodies for puromycinylated protein (1:5000; Proteintech). Scanned images were quantified using ImageJ software.

Measurement of ternary complex activity
---------------------------------------

To obtain pRLSV40 ATF4 5&rsquo;UTR constructs, the human *ATF4* 5&rsquo;UTR (the upstream untranslated region) was amplified using the following primer pair: Forward 5&rsquo;CTGgctagcGCCCTTTTTCTACTTTGCCCG3&rsquo;; Reverse 5&rsquo;CTGCTCAGGgctagcATTTCGGTCATGTTG 3&rsquo;. Upstream 5&rsquo;UTR ATG codons were removed by site-directed mutagenesis to obtain pRLSV40 ATF4 5&rsquo;UTR mutant using the following primer pairs: ATF4 mutant external F 5&rsquo;gctagcGCCCTTTTTCTACTTTGCCCGCCCACAG[AGG]{.ul}TAG3&rsquo;;ATF4 mutant external R 5&rsquo;gctagCATTTCGGTCATGTTGCGGTGCTTTG3&rsquo;;ATF4 mutant internal F 5&rsquo;GTCCACGGCCACC[AGG]{.ul}GCGTATTAGGGGCAG3&rsquo;;ATF4 mutant internal R 5&rsquo;CTGCCCCTAATACGCCCTGGTGGCCGTGGAC3&rsquo;;ATF4 mutant internal F2 5&rsquo;CAGCGGCTTAAGCC[AGG]{.ul}GCGCTTCTCACGG3&rsquo;;ATF4 mutant internal R2 5&rsquo;CCGTGAGAAGCGCCCTGGCTTAAGCCGCTG3&rsquo;.

The PCR product was inserted into the NheI site of the pRLSV40 construct ([@awx074-B24]) upstream of the *Renilla* luciferase coding region, creating pATF4 with the intact ATF4 5&rsquo;UTR, and pATF4mu with the upstream open reading frames removed from the ATF4 5&rsquo;UTR. The internal control firefly luciferase-encoding plasmid pGL3 was purchased from Promega and used to normalize luciferase expression.

CHO cells were grown in 12-well plates and transfected with 200&thinsp;ng reporter plasmid and 30&thinsp;ng control plasmid per well using Lipofectamine&reg; 3000 and the manufacturer&rsquo;s instructions. Twenty-four hours later the cells were stressed with 1&thinsp;&mu;M thapsigargin and treated with either GSK2606414 (5&thinsp;&mu;M), ISRIB (1&thinsp;&mu;M), trazodone (20&thinsp;&mu;M) or DBM (20&thinsp;&mu;M). Cells were lysed after the indicated incubation time using Passive Lysis Buffer (Promega), and 10&thinsp;&micro;l of lysate were assayed using the Dual-Luciferase Reporter Assay System (Promega) on a GloMax&reg; 96 Microplate Luminometer (Promega). For DNA transfections, relative luciferase activity was calculated as a ratio of *Renilla* luciferase (Rluc) to firefly luciferase (Fluc).

Protein synthesis rates in *ex vivo* slices
-------------------------------------------

Protein synthesis rates were calculated by measuring ^35^S-methionine incorporation into proteins in acute hippocampal slices, as described ([@awx074-B27], [@awx074-B26]). In brief, hippocampal slices were prepared with a tissue chopper (McIlwain) and dissected in an oxygenated cold (2--5&deg;C) sucrose artificial CSF containing 26&thinsp;mM NaHCO~3~, 2.5&thinsp;mM KCl, 4&thinsp;mM MgCl~2~, 0.1&thinsp;mM CaCl~2~ and 250&thinsp;mM sucrose. Slices were allowed to recover in normal artificial CSF buffer while being oxygenated at 37&deg;C for 1&thinsp;h in 95&percnt; O~2~/5&percnt; CO~2~, and then incubated with 5.7 mBq of ^35^S-methionine label for 1&thinsp;h. Samples were washed and then homogenized in 1&times; passive lysis buffer (Promega), and proteins were precipitated with 25&percnt; trichloroacetic acid (TCA) (Sigma). TCA lysates were then placed on Whatman filters, washed with 70&percnt; industrial methylated spirits and acetone, and then placed into scintillation cocktail buffer. Incorporation of radiolabel was measured by scintillation counting (WinSpectral, Wallac).

Histology
---------

Paraffin-embedded brain and pancreas were sectioned at 5&thinsp;&mu;m and stained with haematoxylin and eosin or NeuN antibody (1:200; Millipore) for neuronal counts as described ([@awx074-B27], [@awx074-B26]). All images were taken on using AxioVision 4.8 software (Zeiss) and counted using Volocity imaging system. CA1 pyramidal neuron counts were determined using three serial sections from five separate mice ([@awx074-B27], [@awx074-B26]). All neuronal counting was performed with the investigator being blind to the sample group being analysed. Immunohistochemistry for pSer^202^/Thr^205^ tau was performed using AT8 (1:100; Thermo Scientific).

Mice
----

Wild-type FVB mice were obtained from Charles River, UK. rTg4510 tau~P301L~^&plus;^ and tau~P301L~^&minus;^ mice were generated from crossing FVB-Tg(tetO-MAPT^\*^P301L)\#Kha/JlwsJ (015815; The Jackson Laboratory) with B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ (007004; The Jackson Laboratory).

Prion infection of mice
-----------------------

Tg37^&plus;/&minus;^ mice were inoculated with 1&percnt; brain homogenate of Chandler/RML prions aged 3--4 weeks, as described ([@awx074-B21]). Animals were culled when they developed clinical signs of prion disease or lost 20&percnt; of body weight from the start of the study. Control mice received 1&percnt; normal brain homogenate.

Pharmacological treatment of mice
---------------------------------

Mice were intraperitoneally injected once daily with 40&thinsp;mg/kg trazodone hydrochloride or vehicle (sterile saline), or fed powdered diet 5LF2 containing 0.5&percnt; dibenzoylmethane *ad libitum.* Treatment was from 7 weeks post-infection until terminal clinical sign appeared in tg37^&plus;/&minus;^ mice, or from 4 months until 8 months in rTg4510 mice. Sample sizes are based on our previous papers ([@awx074-B27], [@awx074-B26]; [@awx074-B22], [@awx074-B21]), 12--15 mice are used per group as this gives adequate statistical power to detect changes in longevity and behaviour. Mice were randomly assigned a treatment by cage number, and no mice were excluded from the analysis. Experimenters were blind to the treatment group of the mice when clinical signs were being assessed.

Detection of compounds by LC-MS/MS
----------------------------------

Wild-type FVB mice for these experiments were obtained from Charles River. Blood and brain tissue were collected 2 or 8&thinsp;h after dosing from mice treated with one intraperitoneal dose of 40&thinsp;mg/kg trazodone hydrochloride or vehicle. Blood and brain tissue was also collected from mice given free access to food mixture containing 0.5&percnt; dibenzoylmethane for 24&thinsp;h before testing. Blood plasma (up to 0.2&thinsp;ml, exact volume measured) was diluted with water to 0.2&thinsp;ml and extracted with 0.4&thinsp;ml of chloroform:methanol 2:1(v/v). After vortex mixing (10&thinsp;min) and centrifugation (10&thinsp;000*g*, 10&thinsp;min), the lower layer was dried with vacuum centrifugation and reconstituted in 50&thinsp;&mu;l of methanol. Brain tissue (one complete half, &sim;0.25&thinsp;g weighed exactly) was homogenized in 0.5&thinsp;ml of chloroform: methanol 2:1 (v/v) and further processed exactly as the plasma samples. Quantitative analysis (using external standards) was performed by tandem liquid chromatography-mass spectrometry (LC-MS/MS) using a 4000 QTRAP mass spectrometer (Applied Biosystems) equipped with a turbo ion source and LC series 10 AD VP (Shimadzu). The mobile phase was a water/acetonitrile gradient modified with 0.1&percnt; formic acid using an Agilent 2 Poroshell 120 SB-C18 2.1&thinsp;&times;&thinsp;50&thinsp;mm (2.7&thinsp;&mu;m particle size) column, which was maintained at 40&deg;C. LC-MS/MS multiple reaction monitoring used precursors and product ions of mass/charge ratio (*m/z*) 372 and 148 for trazodone and *m/z* 225 and 105 for dibenzoylmethane in positive electrospray ionization mode. Data analysis was carried out with Analyst 1.4.1 in the quantitative mode.

Novel object recognition memory test
------------------------------------

Novel object recognition memory test was carried out as described ([@awx074-B26]). Briefly, mice were tested in a black cylindrical arena (69-cm diameter) mounted with a 100 light-emitting diode cluster infrared light source and a high-resolution day/night video camera (Sony). Mice were acclimatized to the arena 5 days before testing. During the learning phase, two identical objects were placed 15&thinsp;cm from the sides of the arena. Each mouse was placed in the arena for two blocks of 10&thinsp;min for exploration of the objects with an intertrial interval of 10&thinsp;min. Two hours later, one of the objects was exchanged for a new one, and the mouse was replaced in the arena for 5&thinsp;min (test phase). The amount of time spent exploring all objects was tracked and measured for each animal with EthoVision software (Tracksys Ltd). All objects and the arena were cleansed thoroughly between trials to ensure the absence of olfactory cues.

Burrowing
---------

Briefly, mice were placed in a large cage with a Perspex tube full of food pellets, as described ([@awx074-B26]). The natural tendency of rodents is to displace (burrow) the food pellets. The percentage of burrowing activity is calculated from the difference in the weight of pellets in the tube before and after 2&thinsp;h.

Statistical analyses
--------------------

Statistical analyses were performed using Prism V6 software. Data were analysed using one-way ANOVA and Tukey&rsquo;s *post hoc* test for multiple variables. For Kaplan-Meier analysis, Mantel-Cox test was used. All data in bar charts shows mean&thinsp;&plusmn;&thinsp;standard error of the mean (SEM).

Experimental design
-------------------

All animal work conformed to the ARRIVE guidelines, UK Home Office regulations and institutional guidelines. Mice were randomly assigned treatment groups by cage number. Experimenter was blind to group allocation during the experiments and when assessing clinical signs. For behavioural testing no formal randomization was needed or used.

Results
=======

Screening approach of small compound library identifies potential PERK branch UPR inhibitors
--------------------------------------------------------------------------------------------

First, in a novel primary screen, we tested the ability of all 1040 compounds of the NINDS Custom Collection 2 in a phenotypic screen in *C. elegans. C. elegans* have many experimental advantages as a model organism, many of which pertain to drug screening. In contrast to cell lines, they contain many cell types (in particular, a functioning nervous system) and have easily observable phenotypes, increasing the likelihood of detection of representative and translatable effects of drugs on signalling pathways. For this screen, we tested the ability of the NINDS compounds to prevent tunicamycin-induced developmental delay in *C. elegans* ([@awx074-B36]) ([Supplementary material](#sup1){ref-type="supplementary-material"} and [Supplementary Fig. 1](#sup1){ref-type="supplementary-material"}). Briefly, *C. elegans* develop through four larval stages (L1--L4) before reaching adulthood, with a generational time of 3 days. When *C. elegans* are exposed to tunicamycin&mdash;a nucleoside antibiotic that inhibits N-linked glycosylation and induces UPR activation&mdash;from hatching, the development of the majority of worms stalls between the L2 and L3 larval stages. We considered any compound in the screen that overcame the developmental delay as a potential UPR inhibitor suitable for further investigation. Twenty compounds ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}, cropped) of the 1040 screened ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}, full) overcame the tunicamycin-induced developmental delay in the nematodes.

To further delineate the mechanisms of action of the 20 &lsquo;hit&rsquo; compounds, we next used a system in which signal transduction could be further investigated. Tunicamycin is a generic UPR stressor, activating all three UPR branches ([@awx074-B30]). We used a mammalian cell model as a secondary screening system to identify compounds acting through PERK branch mediated eIF2&alpha;-P signalling. eIF2&alpha; phosphorylation leads to general translational repression, while simultaneously stimulating the selective translation of a number of specific mRNAs, including activating transcription factor 4 (*ATF4*). ATF4, in turn induces expression of CHOP. CHOP expression is thus a downstream effect of eIF2&alpha; phosphorylation. To detect activation of the PERK/eIF2&alpha; pathway, we used a CHO cell line containing a reporter construct encoding the *DDIT3* (CHOP) promoter and 5&rsquo; UTR region driving a firefly luciferase transgene ([Fig. 1](#awx074-F1){ref-type="fig"}A). Exposure to UPR stressors induces robust luciferase expression in CHO CHOP::luciferase cells ([@awx074-B7]). Thus, we screened the 20 hit compounds from our primary screen for degree of inhibition of luciferase response to tunicamycin in CHOP::luciferase cells as a measure of inhibition of eIF2&alpha;-P signalling. We were interested in compounds with partial UPR inhibitory activity (as occurs with ISRIB) ([@awx074-B6]), as we previously determined that this allows sufficient restoration of translation rates to protect the brain, without compromising secretory tissue ([@awx074-B6]). Five drugs met the criteria for a &lsquo;hit&rsquo; in this screen. This was defined as a partial reduction in luciferase signal induction in tunicamycin-stressed cells, similar to &sim;50&percnt; inhibition induced by ISRIB. In contrast, GSK2606414 produced almost 100&percnt; inhibition of luciferase signal induction by tunicamycin, consistent with previous findings ([Fig. 1](#awx074-F1){ref-type="fig"}A; [@awx074-B6]).

We selected two of these five, trazodone hydrochloride and DBM, for further testing because of their suitability for treating patients in eventual translational studies. Thus, trazodone, a licensed antidepressant (whose primary action is as a serotonin antagonist and reuptake inhibitor, and which has mild sedative effects due to a degree of histamine receptor activity), is safely used in Alzheimer&rsquo;s disease for management of agitation and insomnia, albeit usually in relatively advanced disease ([@awx074-B23]). Further, in humans, trazodone is rapidly and almost completely absorbed orally, freely crosses the blood--brain barrier and has a biological half-life of &sim;10&thinsp;h. DBM is a naturally occurring structural analogue of curcumin, with widely reported anti-cancer properties ([@awx074-B14]), which has no known toxicity. Two of the other three hits in this screen were rejected because of lack of suitability for eventual translational studies in humans: trifluorperazine is an anti-psychotic contraindicated in the elderly (due to increased risk of death when used to treat behavioural/psychological problems caused by dementia in older people); azadirectin is a pesticide found in neem oil and is poorly brain penetrant. The third hit, proguanil, is an anti-malarial that is safe in humans; however, it is toxic to mice, precluding our carrying out the relevant preclinical experiments. We then tested the effects of increasing concentrations of trazodone and DBM in CHOP::luciferase cells. Both drugs showed a dose-response effect in inhibiting luciferase expression in the reporter cell line reaching a plateau at 50&thinsp;&mu;M concentration, consistent with an intrinsic limitation of inhibitory activity ([Fig. 1](#awx074-F1){ref-type="fig"}B), as reported for ISRIB ([@awx074-B6]).

Trazodone and dibenzoylmethane inhibit UPR-induced eIF2&alpha;-P signalling and restore protein synthesis rates *in&nbsp;vitro*
-------------------------------------------------------------------------------------------------------------------------------

We then tested both compounds to identify their site of action in the pathway ([Fig. 2](#awx074-F2){ref-type="fig"}A). Both trazodone and DBM (20&thinsp;&mu;M) reduced ATF4 levels, but not eIF2&alpha;-P levels in tunicamycin stressed cells ([Fig. 2](#awx074-F2){ref-type="fig"}B), placing their site of action downstream of eIF2&alpha;-P, like ISRIB. Consistent with inhibition of eIF2&alpha;-P activity, DBM and trazodone partially restored protein synthesis rates in tunicamycin-treated cells ([Fig. 2](#awx074-F2){ref-type="fig"}C). Due to the apparent similarities between trazodone and DBM and the mechanism of action of ISRIB (which stabilizes eIF2B, facilitating ternary complex formation) ([@awx074-B39]; [@awx074-B41]), we next determined if the compounds exerted a similar effect on eIF2B and ternary complex levels as ISRIB. Under normal circumstances, eIF2&alpha;-P reduces ternary complex availability for initiation of translation, reducing protein synthesis rates. However, selected mRNAs, including *ATF4*, are able to overcome this block on translation due to the structure of their upstream translated region (5&rsquo;UTR) that contains multiple upstream open reading frames ([@awx074-B49]) and are translated more efficiently when eIF2&alpha;-P levels are high. We used a luciferase reporter construct downstream of the *ATF4* 5&rsquo;UTR to transfect cells. The *ATF4* 5&rsquo;UTR directly responds to reduced levels of ternary complex, resulting in activation of luciferase when eIF2&alpha;-P levels are high, as on UPR induction. Following activation of the UPR by thapsigargin treatment in transfected CHO cells, both trazodone and dibenzoylmethane, like ISRIB, prevented the wild-type *ATF4* 5&rsquo;UTR activation normally associated with endoplasmic reticulum stress ([Fig. 2](#awx074-F2){ref-type="fig"}D). This effect is lost when the ATF4 5&rsquo;UTR with the upstream open reading frames removed by a single nucleotide substitution of the upstream ATG start codons is expressed and treated in the same manner. Thus, these compounds prevent eIF2&alpha;-P from reducing ternary complex levels, allowing translation to proceed when eIF2&alpha;-P levels are high. Figure 2**Trazodone and DBM inhibit UPR-induced eIF2&alpha;-P signalling *in&nbsp;vitro.*** (**A**) Schematic of the UPR, showing site of action of compounds modulating PERK branch dysregulation. (**B**) Western blots showing DBM and trazodone reduce ATF4 levels without affecting eIF2&alpha;-P levels; bar graphs on *right* show quantitation. Repeated in triplicate. (**C**) DBM and trazodone partially restore protein synthesis rates after thapsigargin (1&thinsp;&mu;M) stress in HEK293 cells, assessed by puromycin incorporation into nascent proteins quantified from western blots. Repeated in triplicate. (**D**) Trazodone and DBM reduce luciferase expression under control of the *ATF4* 5&rsquo;UTR (pATF4), but have no effect when upstream open reading frames in the 5&rsquo;UTR are removed (pATF4mu), demonstrating an ability to increase ternary complex levels. Levels of pATF4 and pATF4mu normalized to firefly luciferase expressed by the pGL3 plasmid in CHO cells stressed with 1&thinsp;&mu;M thapsigargin for 6&thinsp;h. *n*&thinsp;&equals;&thinsp;3, repeated in triplicate. (**E**) *XBP1* splicing is unchanged by DBM or trazodone after 3&thinsp;h tunicamycin stress, determined by RT-PCR, or after 6&thinsp;h stress and measured by quantitative PCR (**F**). (**G**) Full-length ATF6 (flATF6) cleavage to nuclear fragment (nATG6) is not affected by DBM or trazodone. Repeated in triplicate. All bar charts show means&thinsp;&plusmn;&thinsp;SEM. ^\*^*P*&thinsp;&lt;&thinsp;0.05, ^\*\*^*P*&thinsp;&lt;&thinsp;0.01, ^\*\*\*^*P*&thinsp;&lt;&thinsp;0.001, n.s.&thinsp;&equals;&thinsp;non-significant. One-way ANOVA and Tukey&rsquo;s *post hoc* test.

We next investigated if trazodone and DBM affect eIF2B dimerization in the same way as ISRIB ([@awx074-B41]). We observed that ISRIB caused a shift in both eIF2B&delta; and eIF2B&varepsilon; subunit distribution in sucrose gradients consistent with increased dimerization of eIF2B, in agreement with previously published work ([@awx074-B41]). However, neither trazodone nor DBM caused dimerization of eIF2B ([Supplementary Fig. 2](#sup1){ref-type="supplementary-material"}). Thus, the data show that while these drugs act at a similar level to ISRIB to uncouple eIF2&alpha;-P-mediated reduction of ternary complex, they are functioning via distinct mechanisms.

The compounds did not, however, act on the other UPR branches, having no effect on tunicamycin-induced *XBP1* splicing, as detected by PCR ([Fig. 2](#awx074-F2){ref-type="fig"}E), or measured semiquantitatively by quantitative PCR ([Fig. 2](#awx074-F2){ref-type="fig"}F), or cleavage of ATF6 ([Fig. 2](#awx074-F2){ref-type="fig"}G). Thus, these data, together with the evidence from our primary and secondary screens, support activity for both trazodone and DBM in restoring translation rates *in&nbsp;vitro* under conditions of UPR stress. Further, the evidence shows that both compounds show partial inhibition of UPR-mediated translational repression ([Fig. 1](#awx074-F1){ref-type="fig"}A) and have an intrinsic limitation in this activity ([Fig. 1](#awx074-F1){ref-type="fig"}B), as previously seen with ISRIB ([@awx074-B6]). This is important, because this is known to be a safe level of UPR/ISR reversal *in&nbsp;vivo*, in contrast to the toxicity produced by complete inhibition of this signalling, as occurs with the PERK inhibitor, GSK2606414 ([@awx074-B26]). Also, like ISRIB, it appears that the site of action of both trazodone and DBM in inhibiting this activity is downstream of eIF2&alpha;-P, at the level of ternary complex ([Fig. 2](#awx074-F2){ref-type="fig"}D). Given these favourable *in&nbsp;vitro* features, both compounds were put forward for testing in preclinical mouse models of neurodegenerative disease in which ISRIB and/or GSK2606414 have been shown to be neuroprotective (despite pancreatic toxicity of the latter compound) ([@awx074-B26]; [@awx074-B6]; [@awx074-B33]).

Trazodone and dibenzoylmethane penetrate the blood--brain barrier
-----------------------------------------------------------------

We next tested the therapeutic effects of trazodone and DBM *in&nbsp;vivo.* For clinical relevance, we used a daily dose of 40&thinsp;mg/kg of trazodone delivered intraperitoneally in mice, equivalent to 194 mg/day in humans. Patients usually receive 150--375&thinsp;mg trazodone per day. We used a standard conversion formula for dose translation to calculate the corresponding mouse dose ([@awx074-B35]). DBM oral suspension was provided in food as a 0.5&percnt; mixture available *ad libitum,* as described ([@awx074-B14]). Pharmacokinetic data pertaining to plasma levels and brain penetration were investigated by quantitative LC-MS/MS measurements in brain and plasma samples in wild-type mice. Trazodone levels were measured at 2 and 8&thinsp;h post-administration; DBM levels were measured after 24&thinsp;h, to allow for sufficient consumption of food containing the compound. The data confirmed both drugs penetrated the blood--brain barrier with mean brain:plasma ratios consistent with efficacious dosing ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}).

Trazodone and dibenzoylmethane prevent neurological signs of prion disease in prion-infected mice
-------------------------------------------------------------------------------------------------

We first tested the drugs in mice with prion disease, for comparison of their therapeutic efficacy with that of the experimental compounds GSK2606414 and ISRIB ([@awx074-B26]; [@awx074-B6]; [@awx074-B33]). We used hemizygous tg37^&plus;/&minus;^ mice (see below), as in our previous investigations ([@awx074-B22], [@awx074-B21]; [@awx074-B27], [@awx074-B26]; [@awx074-B6]; [@awx074-B33]) so that we could directly compare the efficacy of trazodone and DBM with previous genetic and pharmacological approaches. These mice overexpress PrP at &sim;3-fold wild-type levels and therefore have a relatively rapid prion incubation time, succumbing to intracerebral Rocky Mountain laboratory (RML) prion inoculation at &sim;12 weeks post-infection (&sim;84 days) ([@awx074-B22]). Misfolded PrP is detectable by 5--6 weeks post-infection, regenerative capacity is impaired at 6 weeks post-infection ([@awx074-B31]) and overt synapse loss occurs from 7 weeks post-infection in RML-infected tg37^&plus;/&minus;^ mice ([@awx074-B27]). Dysregulated PERK signalling leads to eIF2&alpha;-P-mediated translational repression from &sim;9 weeks post-infection, when cognitive deficits and memory loss are detected. Irreversible neurodegeneration occurs at 10 weeks post-infection, with signs of clinical neurological disease evident by 12 weeks post-infection ([@awx074-B27]) ([Fig. 3](#awx074-F3){ref-type="fig"}A). Restoring translation rates either upstream of eIF2&alpha;-P by inhibiting PERK with GSK2606414 ([@awx074-B26]), or downstream using ISRIB ([@awx074-B6]), has previously been shown to prevent clinical disease and neurodegeneration in prion-infected mice, independent of PrP levels. As in our previous studies ([@awx074-B26]; [@awx074-B6]), RML-infected tg37^&plus;/&minus;^ mice were treated daily with trazodone, DBM or vehicle from 7 weeks post-infection, a time point when early degenerative changes&mdash;specifically synapse loss and spongiosis&mdash;are established, and which are considered equivalent to early stage symptoms of cognitive impairment in humans ([@awx074-B27]). We used tg37^&plus;/&minus;^ mice, as opposed to wild-type, in these as in our previous experiments, as we have previously shown UPR activation occurs in both strains, with identical effects on protein synthesis rates and clinical signs and neuronal loss, differing only in time course of disease ([@awx074-B27]). In line with local animal husbandry guidelines, we use the mice with shorter disease course. Figure 3**Trazodone and DBM are neuroprotective in prion disease**. (**A**) Schematic of prion disease course in tg37^&plus;/&minus;^ mice. (**B**) Representative images (chosen from *n*&thinsp;&equals;&thinsp;10--12) of haematoxylin and eosin stained hippocampal and pancreatic sections, from uninfected controls and prion-infected mice treated with vehicle, trazodone and DBM. Both drugs are markedly neuroprotective (**vii**, **viii** compared to **vi**) and do not harm the pancreas (**xi** and **xii**). Scale bars&thinsp;&equals;&thinsp;400&thinsp;&mu;m (**i--iv**), 50&thinsp;&mu;m (**v--viii**) 200&thinsp;&mu;m (**ix--xii**). (**C**) Neuronal counts of CA1 region (*n*&thinsp;&equals;&thinsp;5 mice for each condition, with three slices counted from each animal). (**D**) Both drugs prevent loss of object recognition memory and (**E**) DBM prevents decline in burrowing behaviour at 9 and 10 weeks post-infection (*n*&thinsp;&equals;&thinsp;15 for each group) (**F**) Kaplan-Meier plot shows significantly increased survival with DBM (*n*&thinsp;&equals;&thinsp;21) and trazodone (*n*&thinsp;&equals;&thinsp;15) compared to vehicle (*n*&thinsp;&equals;&thinsp;20) treatment, ^\*^*P*&thinsp;&lt;&thinsp;0.05, Mantel--Cox analysis used. (**G**) Weights loss occurs in prion infected mice but not uninfected control, regardless of drug dosing. Normal brain homogenate, treated with trazodone (light blue) or DBM (yellow) *n*&thinsp;&equals;&thinsp;5. Prion infected mice treated with vehicle (black, *n*&thinsp;&equals;&thinsp;20) trazodone (dark blue, *n*&thinsp;&equals;&thinsp;15) or DBM (magenta *n*&thinsp;&equals;&thinsp;21). (**H**) Western blots show high levels of eIF2&alpha;-P in prion-disease brains are unaffected by treatment with DBM and trazodone, but ATF4 levels are significantly reduced; bar graphs on right show quantitation relative to loading controls (*n*&thinsp;&equals;&thinsp;3; repeated in triplicate). (**I**) DBM and trazodone restore global protein synthesis rates measured by ^35^S-met incorporation into hippocampal slices at 10 weeks post-infection (*n*&thinsp;&equals;&thinsp;6 per treatment group). (**J**) Levels of misfolded PrP, PrP^Sc^, detected after PK digestion from brains of terminally sick mice is unaffected by either drug. All bar charts show means&thinsp;&plusmn;&thinsp;SEM; ^\*^*P*&thinsp;&lt;&thinsp;0.05, ^\*\*^*P*&thinsp;&lt;&thinsp;0.01, ^\*\*\*^*P*&thinsp;&lt;&thinsp;0.001, n.s.&thinsp;&equals;&thinsp;non-significant, one-way ANOVA with Tukey&rsquo;s *post hoc* test.

All mice were observed for effects of treatment with trazodone or DBM compared to vehicle on their clinical progression. Clinically confirmed prion disease in mice (which is terminal) is diagnosed by the appearance of a range of clinical signs indicative of neurological disease. These include the appearance of at least one of several possible early indicator signs (which are on their own non-specific) in combination with at least one of several possible confirmatory signs ([Table 1](#awx074-T1){ref-type="table"}). Confirmatory signs occur later in disease, when neuronal loss is advanced, and at least one is required for diagnosis. (Some, for example, impaired righting reflex occur more commonly than others). All 20 prion-infected mice treated with vehicle developed one or more confirmatory clinical signs and succumbed to prion infection in 83&thinsp;&plusmn;&thinsp;2 days ([Table 1](#awx074-T1){ref-type="table"}), consistent with previous data ([@awx074-B22], [@awx074-B21]; [@awx074-B27], [@awx074-B26]; [@awx074-B6]; [@awx074-B33]). Remarkably, both trazodone and DBM treatment prevented the appearance of confirmatory neurological signs diagnostic of clinical prion disease in majority of treated animals. Twelve of 15 (80&percnt;) prion-infected mice treated with trazodone and 16/21 mice (71&percnt;) treated with DBM, did not show diagnostic neurological signs of prion disease at the point of culling. While all animals developed non-specific early signs, most of these were not sustained and only 3/15 mice (trazodone) and 6/21 mice (DBM) progressed to develop prion confirmatory neurological signs.Table 1Trazodone and DBM prevent clinical signs of neurological prion disease in most miceClinical signs used in diagnosis of neurologically definite prion diseaseVehicleTrazodoneDBMEarly indicator signs (not diagnostic of clinical prion disease in absence of confirmatory signs)&emsp;Hind limb clasping13/203/159/21&emsp;Unsustained hunched posture1/202/157/21&emsp;Mild loss of coordination20/2014/1517/21Confirmatory signs (two confirmatory signs or one in combination with early indicator signs for diagnosis of clinical prion disease)&emsp;Impairment of righting reflex18/202/155/21&emsp;Dragging of limbs1/200/150/21&emsp;Sustained hunched posture0/201/151/21&emsp;Abnormal breathing1/200/150/21Animals with clinical prion disease (at point of culling), *n* (time to diagnosis, days&thinsp;&plusmn;&thinsp;SEM)20/20 (83&thinsp;&plusmn;&thinsp;2)3/15 (83&thinsp;&plusmn;&thinsp;4)6/21 (84&thinsp;&plusmn;&thinsp;4)Animals not manifesting neurological signs of prion disease (at point of culling), *n*0/2012/1515/21[^2]

Thus, both trazodone and DBM prevented development of neurological disease in the majority of treated animals: those animals developing confirmatory clinical signs and succumbing to prion infection may have received lower doses of drug, particularly in the DBM group, where drug levels were dependent on food consumption and varied between mice.

Trazodone and dibenzoylmethane prevent neurodegeneration and rescue behavioural deficits in prion-infected mice without pancreatic toxicity
-------------------------------------------------------------------------------------------------------------------------------------------

Consistent with clinical efficacy of trazodone and DBM in preventing clinical signs of neurodegeneration, both drugs were markedly neuroprotective at the histological level in prion-infected mice. Thus, both drugs substantially reduced neuronal loss in the hippocampus in those mice in which they prevented neurological signs of prion disease. In contrast, vehicle-treated mice had extensive atrophy of CA1-3 hippocampal cells at the time of sacrifice, when they also had confirmed clinical diagnosis of prion disease. This is markedly different to the protective effects of both trazodone and DBM treatment on hippocampal morphology and integrity \[[Fig. 3](#awx074-F3){ref-type="fig"}B(ii--iv) and (vi--viii)\]. Indeed, neuronal counts from CA1 regions confirmed significant protective effects of both trazodone and DBM ([Fig. 3](#awx074-F3){ref-type="fig"}C). Critically, neither drug produced any pancreatic toxicity of either endocrine or exocrine tissue \[[Fig. 3](#awx074-F3){ref-type="fig"}B(ix--xii), [Supplementary Fig. 3A](#sup1){ref-type="supplementary-material"} and B\]. Both compounds rescued the loss of object recognition memory at 9 weeks post-infection ([Fig. 3](#awx074-F3){ref-type="fig"}D), and DBM also prevented loss of burrowing behaviour characteristic of prion infection at 9 and 10 weeks post-infection ([@awx074-B27], [@awx074-B26]) ([Fig. 3](#awx074-F3){ref-type="fig"}E). (Trazodone treatment precluded testing for burrowing activity due to effects of sedation immediately after dosing, reducing spontaneous activity. Sedation was not sustained, but nonetheless it did not permit testing within the relevant period).

Trazodone and dibenzoylmethane significantly increase survival in prion-infected mice
-------------------------------------------------------------------------------------

Importantly, both drugs significantly increased lifespan in the 12/15 trazodone-treated and 15/21 DBM-treated animals that did not show neurological signs of prion infection (*P*&thinsp;&equals;&thinsp;0.0103) ([Fig. 3](#awx074-F3){ref-type="fig"}F). However, the increase in lifespan was less prolonged than would have been expected, given both the lack of diagnostic signs of prion disease seen clinically ([Table 1](#awx074-T1){ref-type="table"}) and the extent of neuroprotection seen histologically ([Fig. 3](#awx074-F3){ref-type="fig"}B). This occurred as, in accordance with UK Home Office regulations, these mice had to be culled because of weight loss of 20&percnt; of their original body weight, despite being devoid of neurological signs of prion disease and being otherwise in every way clinically well ([Fig. 3](#awx074-F3){ref-type="fig"}G). This very likely masked probable much longer-lasting clinical efficacy of treatment with trazodone or DBM. Importantly, weight loss was not an effect of treatment with trazodone or DBM in itself. Control mice, inoculated with normal brain homogenate and treated with the drugs over the same time period, did not lose weight ([Fig. 3](#awx074-F3){ref-type="fig"}G). Further, the rTg4510 tauopathy mice did not lose weight with trazodone or DBM treatment ([Fig. 4](#awx074-F4){ref-type="fig"}G), even though treatment lasted for several months before the animals were sacrificed for analysis. Figure 4**Trazodone and DBM are neuroprotective in rTg4510 model of the tauopathy FTD.** (**A**) Schematic of disease progression in rTg4510 tau~P301L~&plus; mice. (**B**) Representative images (chosen from *n*&thinsp;&equals;&thinsp;10--12) of hippocampal sections from 8-month-old mice stained with haematoxylin and eosin (**i--viii**) and pSer^202^/Thr^205^-tau (**ix--xii**) from tau~P301L~&minus; control mice and tau~P301L~&plus; mice treated with vehicle, trazodone or DBM. Scale bars&thinsp;&equals;&thinsp;400&thinsp;&mu;m (**i--iv**), 50&thinsp;&mu;m (**v--xii**). (**C**) Neuronal counts of CA1 region at 8 months (*n*&thinsp;&equals;&thinsp;5 for each condition, three consecutive slices). (**D**) Both drugs prevent loss of object recognition memory (*n*&thinsp;&equals;&thinsp;12 for each group). (**E**) Quantification of p-tau levels measured by the AT100 antibody. Trazodone but not DBM reduces levels. *n*&thinsp;&equals;&thinsp;3 mice per group. (**F**) Trazodone and DBM do not cause weight loss in rTG4510 mice during the 4-month dosing period, *n*&thinsp;&equals;&thinsp;10 per group. (**G**) Protein levels of ATF4 are reduced after treatment with trazodone or DBM compared to vehicle; however, eIF2&alpha;-P and eIF2&alpha; levels do not change. Repeated in triplicate. (**H**) DBM and trazodone partially restore global protein synthesis rates measured by ^35^S-met incorporation into hippocampal slices at 8 months (*n*&thinsp;&equals;&thinsp;4 per treatment group). All bar charts show mean&thinsp;&plusmn;&thinsp;SEM. ^\*^*P*&thinsp;&lt;&thinsp;0.05, n.s.&thinsp;&equals;&thinsp;non-significant, using one-way ANOVA and Tukey&rsquo;s *post hoc* analysis.

Thus, it appears that loss of body mass is a feature of systemic prion infection (albeit not associated with other signs of ill-health), which we have previously also described with ISRIB treatment ([@awx074-B6]). With both trazodone and DBM, as with ISRIB, this feature of prion infection is dissociated from the neuroprotective effects of treatment.

Trazodone and dibenzoylmethane restore protein synthesis downstream of eIF2&alpha;-P in prion-diseased mice
-----------------------------------------------------------------------------------------------------------

The site of action of both compounds *in&nbsp;vivo* is downstream of eIF2&alpha;-P, in agreement with our *in&nbsp;vitro* findings. Thus, elevated eIF2&alpha;-P levels in prion-diseased hippocampi were unchanged by treatment with trazodone and DBM, while ATF4 levels were reduced ([Fig. 3](#awx074-F3){ref-type="fig"}H), replicating our observations *in&nbsp;vitro* ([Fig. 2](#awx074-F2){ref-type="fig"}B and D). Consistent with this, both drugs increased protein synthesis rates in *ex vivo* hippocampal slices compared to &sim;60&percnt; reduction in protein synthesis rates seen in the brains of vehicle-treated animals ([Fig. 3](#awx074-F3){ref-type="fig"}I). DBM and trazodone treatment had no effect on the levels of misfolded PrP levels (PrP^Sc^) ([Fig. 3](#awx074-F3){ref-type="fig"}J), consistent with the fact that neuroprotection is likely due to effects on eIF2&alpha;-P signalling, not on prion replication.

Trazodone and dibenzoylmethane are neuroprotective in the rTg4510 model of frontotemporal dementia
--------------------------------------------------------------------------------------------------

PERK branch UPR activation is seen in human tauopathies, including Alzheimer&rsquo;s disease and progressive supranuclear palsy ([@awx074-B12]; [@awx074-B45]). We thus tested trazodone and DBM in a mouse model of tauopathy. rTg4510 mice overexpress the human tau mutation P301L associated with FTD, with onset of tau pathology from 3 months of age ([@awx074-B38]). Raised eIF2&alpha;-P and ATF4 levels and a decline in protein synthesis rates, associated with the onset of neurodegeneration, occur at between 5--6 months of age, becoming severe&mdash;with marked forebrain atrophy&mdash;by 8 months of age ([Fig. 4](#awx074-F4){ref-type="fig"}A). Treatment of tau~P301L~^&plus;^ mice with PERK inhibitor GSK2606414 has been shown to be neuroprotective ([@awx074-B33]). Thus, tau~P301L~^&plus;^ mice received trazodone or DBM daily from 4 months and were examined at 8 months, when neuronal loss is advanced in the CA1 region of untreated (vehicle-treated) mice compared to transgene negative tau~P301L~^&minus;^ mice ([Fig. 4](#awx074-F4){ref-type="fig"}B), with shrinkage of whole hippocampus in tau~P301L~^&plus;^ mice ([Fig. 4](#awx074-F4){ref-type="fig"}B) ([@awx074-B34]; [@awx074-B38]). Trazodone and DBM reduced hippocampal atrophy in rTg4510 mice compared to vehicle treatment, where this was pronounced \[[Fig. 4](#awx074-F4){ref-type="fig"}B, *cf.* (ii), (iii) and (iv), and [Fig. 4](#awx074-F4){ref-type="fig"}C\]. They were notably neuroprotective in the hippocampus, significantly reducing loss of CA1 pyramidal neurons compared to tau~P301L~^&plus;^ mice treated with vehicle \[[Fig. 4](#awx074-F4){ref-type="fig"}B, *cf.* (vi), (vii) and (viii), and [Fig. 4](#awx074-F4){ref-type="fig"}C\]. As in the prion-infected mice, treatment was not toxic to the pancreas \[[Fig. 4](#awx074-F4){ref-type="fig"}B(xiii--xvi), [Supplementary Fig. 3C](#sup1){ref-type="supplementary-material"} and D\]. Both compounds rescued the loss of object recognition memory at 5 months. ([Fig. 4](#awx074-F4){ref-type="fig"}D). Trazodone also produced a reduction in p-tau staining at 8 months compared to vehicle- or DBM-treated mice \[[Fig. 4](#awx074-F4){ref-type="fig"}B, *cf.* (xi) to (x) or (xii), and [Fig. 4](#awx074-F4){ref-type="fig"}E\]. This is likely due to inhibition of the tau kinase GSK3&beta; by phosphorylation at Ser9 induced by trazodone (Supplementary Fig. 4) ([@awx074-B33]). The life-span of rTg4510 mice is long ([@awx074-B34]), so survival studies were not possible as an outcome of treatment, but the effects on hippocampal volume and neuronal integrity and on the general condition of the mice was marked with both drugs. Of note, both drugs were well tolerated for the duration of the experiment&mdash;several months treatment. Importantly, drug treatment did not have any effect on weight loss ([Fig. 4](#awx074-F4){ref-type="fig"}F).

As in prion-infected mice, both compounds reduced ATF4 levels in the brains of rTg4510 without lowering eIF2&alpha;-P levels ([Fig. 4](#awx074-F4){ref-type="fig"}G), supporting a site of action downstream of eIF2&alpha;-P, as seen *in&nbsp;vitro* ([Fig. 2](#awx074-F2){ref-type="fig"}B and D). Trazodone and DBM also partially restored protein synthesis rates in tauopathy-treated mice ([Fig. 4](#awx074-F4){ref-type="fig"}H), again consistent with inhibition of signalling at this level.

Discussion
==========

There is a tremendous unmet clinical need for effective pharmacological interventions against protein-misfolding neurodegenerative disorders such as Alzheimer&rsquo;s and Parkinson&rsquo;s diseases. The PERK branch of the UPR, in particular, has emerged as a promising new therapeutic target in these disorders, due to its overactivation in human Alzheimer&rsquo;s disease brain tissue and mechanistic implications from disease models ([@awx074-B10]; Halliday and Mallucci, 2014). Thus, in preclinical models, many lines of evidence support increased signalling via eIF2&alpha;-P&mdash;and the ensuing attenuation of protein synthesis rates&mdash;as contributing to cognitive impairment and disease progression ([@awx074-B27], [@awx074-B26]; [@awx074-B20]; [@awx074-B2]; [@awx074-B15]; [@awx074-B6]; [@awx074-B33]). Moreover, two compounds, the PERK inhibitor GSK2606414 ([@awx074-B26]) and the ISR inhibitor ISRIB ([@awx074-B6]) have been shown to interfere with the translational inhibitory effects of increased eIF2&alpha; phosphorylation (acting upstream and downstream of eIF2&alpha;-P, respectively). Both of these compounds have been shown to have significant neuroprotective effects in mouse models of neurodegeneration, reducing disease progression ([@awx074-B26]; [@awx074-B6]; [@awx074-B33]). GSK2606414 also improves neuronal phenotypes in fly models of disease ([@awx074-B15]; [@awx074-B1]). Further, ISRIB boosts cognition in wild-type mice ([@awx074-B40]). However, neither of these substances is suitable for translation to treatment of human disease, due to associated toxicity (GSK2606414) or insolubility (ISRIB) ([@awx074-B26]; [@awx074-B6]). There is therefore an urgent need to find safe compounds with similar therapeutic effects to test the potential efficacy of this approach in human disease. This need drove us to develop new screens to find potential repurposable drugs for translation to the clinic as new disease-modifying treatments for dementia.

The development of experimental models amenable to live animal compound screening is an attractive approach for discovering effective pharmacological therapies. Drug screens are often a balance between choosing the most biologically relevant readout, and maintaining a high-enough throughput to remain useful. We chose the nematode worm *C. elegans* for our primary *in&nbsp;vivo* screen due to the worms&rsquo; quick generational time, the ability to breed hundreds of developmentally synchronized animals for testing and easily observable phenotypes. Importantly, the UPR is conserved across metazoa, and *C. elegans* contains orthologues of all the major UPR genes. Tunicamycin induces developmental arrest in the worms at stages L2/L3. This likely occurs as they normally greatly increase in size between the L2 and L3 stages, requiring large amounts of new protein synthesis, which is attenuated by tunicamycin ([Supplementary Fig. 1](#sup1){ref-type="supplementary-material"}). Due to the large difference in size between worms that were stalled at the L2 stage and older worms that had overcome the developmental block, compounds that exerted any beneficial effects were easily observed ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). We used a NINDS Custom Collection 2 drug library including mostly FDA-approved drugs, many of which were known to be brain-penetrant and neurologically active in humans. Twenty of the 1040 NINDS compounds overcame the developmental delay in tunicamycin-stressed worms and were therefore potential UPR inhibitors ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). However, this screen did not determine whether the drugs were direct inhibitors of the UPR. The upregulation of chaperones, or the drugs themselves acting as chemical chaperones, could similarly facilitate normal development in the worms. We therefore screened the 20 hits in mammalian CHO CHOP::luciferase cells to test for inhibition of PERK-mediated UPR signalling ([Fig. 1](#awx074-F1){ref-type="fig"}A and B). Five of the 20 compounds repressed CHOP::luciferase signalling induced by tunicamycin. Of these, trazodone, a licensed anti-depressant safe to use in the elderly, with excellent oral pharmacokinetic profile and excellent safety profile and DBM, a curcumin analogue with notable anti-cancer properties in preclinical models, were the best candidates to take forward.

Trazodone is an antidepressant in the serotonin antagonist and reuptake inhibitor class, which has additional anxiolytic and hypnotic effects. It has been shown to reduce the behavioural and psychological symptoms of dementia (BPSD) in Alzheimer&rsquo;s disease ([@awx074-B19]) and in FTD ([@awx074-B18]), but no studies have looked at the progression of neurodegeneration with trazodone treatment. Although its pharmacological actions in humans are not fully understood, it is thought to have more than one mechanism of therapeutic action, making it a multifunctional drug. It is the first antidepressant with a dual mechanism of action involving inhibition of the serotonin transporter (SERT) and antagonism of the serotonin type 2 (5-HT2) receptor, producing its antidepressant effect by blocking SERT, and increasing serotonin concentrations in the brain. Trazodone exerts antagonistic properties against &alpha;1- and &alpha;2-adrenergic receptors and histamine H1 receptors, with minimal anticholinergic effects ([@awx074-B25]; [@awx074-B44]). Trazodone has previously shown benefit in models of Huntington&rsquo;s disease, where it improved mitochondrial respiratory complex activity ([@awx074-B17]) and Morris water maze performance ([@awx074-B16])

DBM is a minor constituent of liquorice that has been found to have antineoplastic effects, with efficacy against prostate and mammary tumours ([@awx074-B13]; [@awx074-B14]). Carcinogen detoxification has been proposed as a possible mechanism of action as DBM has been reported to potently induce phase 2 hepatic detoxification enzymes ([@awx074-B3]). DBM has also been reported to induce the Nrf2 survival pathway ([@awx074-B47]), which is activated downstream of UPR activation ([@awx074-B8]). DBM has also been shown to upregulate GRP78/BiP ([@awx074-B4]). DBM derivatives have been shown to induce protection from necrotic cell death ([@awx074-B9]) and protect dopaminergic neurons against both oxidative stress and endoplasmic reticulum stress ([@awx074-B46]). It is unclear if DBM itself shares these effects with its derivatives.

In this study, we found that both trazodone and DBM inhibited the effects of UPR activation and eIF2&alpha; phosphorylation, reversing translational attenuation and lowering levels of ATF4 and CHOP in mammalian cells ([Figs 1](#awx074-F1){ref-type="fig"}A and [2](#awx074-F2){ref-type="fig"}B). This occurred without lowering eIF2&alpha;-P levels *in&nbsp;vitro* ([Fig. 2](#awx074-F2){ref-type="fig"}B), and *in&nbsp;vivo* ([Figs 3](#awx074-F3){ref-type="fig"}H and [4](#awx074-F4){ref-type="fig"}G), as has been described for ISRIB ([@awx074-B6]; [@awx074-B39]; [@awx074-B41]). Both trazodone and DBM prevented eIF2&alpha;-P from lowering ternary complex levels, due to their ability to reduce ATF4 5&rsquo;UTR regulation of luciferase ([Fig. 2](#awx074-F2){ref-type="fig"}D), but this was via an independent mechanism than that of ISRIB ([Supplementary Fig. 2](#sup1){ref-type="supplementary-material"}).

Based on their ability to reverse UPR activation, trazodone and DBM were predicted to be potential therapeutic candidates for neurodegenerative disorders. Indeed, both compounds were found to be substantially neuroprotective in two different mouse models of neurodegeneration, prion disease and the rTg4510 tauopathy model of FTD. Both drugs showed beneficial neuroprotective effects similar to those of the experimental compounds GSK2606414 and ISRIB. Importantly, in both models, the drugs were first administered at a stage of early but established disease, equivalent to early symptomatic human disease&mdash;from 7 weeks post-infection in prion-disease mice and from 4 months of age in tauopathy mice. Treatment with each drug prevented neuronal loss in the hippocampus ([Fig. 3](#awx074-F3){ref-type="fig"}B and C) and confirmatory neurological clinical signs ([Table 1](#awx074-T1){ref-type="table"}) in the majority of prion-infected mice, also restoring memory and preventing behavioural decline associated with prion infection ([Fig. 3](#awx074-F3){ref-type="fig"}D and E). In tauopathy mice, both drugs were strongly protective against the marked hippocampal neuronal loss and forebrain atrophy that is a feature of this mouse model ([Fig. 4](#awx074-F4){ref-type="fig"}B and C). These mice were also devoid of clinical signs of neurodegeneration. There was also significant increase in lifespan of prion-infected mice treated with trazodone or DBM ([Fig. 3](#awx074-F3){ref-type="fig"}F), although this was more modest than was expected considering the neuroprotection observed, due to coincidental weight loss requiring early sacrifice of otherwise entirely healthy animals ([Fig. 3](#awx074-F3){ref-type="fig"}G). This weight loss was not caused by trazodone or DBM ([Figs 3](#awx074-F3){ref-type="fig"}G and [4](#awx074-F4){ref-type="fig"}F), which, critically, were also devoid of pancreatic toxicity \[[Figs 3](#awx074-F3){ref-type="fig"}B(ix--xii), 4B(xiii--xvi) and [Supplementary Fig. 2](#sup1){ref-type="supplementary-material"}), likely because both compounds only partially reverse eIF2&alpha;-P-mediated translational attenuation ([Fig. 1](#awx074-F1){ref-type="fig"}A and B), which is associated with lack of toxicity to secretory tissue ([@awx074-B6]). Thus, neither trazodone nor DBM suffer from the shortcomings of GSK2606414 and ISRIB: they are non-toxic to the pancreas and have favourable pharmacokinetic properties. Critically, however, they share the benefits of GSK2606414 and ISRIB, being markedly neuroprotective.

Interestingly, another unanticipated and previously unreported action of trazodone was to lower phosphorylated (p)-tau levels in rTg4510 mice ([Fig. 4](#awx074-F4){ref-type="fig"}B, E and [Supplementary Fig. 4](#sup1){ref-type="supplementary-material"}). P-tau is associated with Alzheimer&rsquo;s disease pathology and with the tauopathies FTD and progressive supranuclear palsy, and is in itself an intense focus for Alzheimer&rsquo;s therapeutics. This additional effect of trazodone could be considered a desirable bonus in the treatment of these disorders. UPR activation is known to induce tau phosphorylation via activation of GSK3&beta; ([@awx074-B28]) and treatment with the PERK inhibitor GSK2606414 also lowers tau phosphorylation ([@awx074-B48]; [@awx074-B33]). Trazodone was also able to inhibit GSK3&beta; ([Supplementary Fig. 4](#sup1){ref-type="supplementary-material"}). However, the similar degree of neuroprotection afforded by trazodone and DBM ([Table 1](#awx074-T1){ref-type="table"}, [Figs 3](#awx074-F3){ref-type="fig"}B, C, 4B and C) suggests that reduction of the stress response downstream of eIF2&alpha;-P and partial restoration of protein synthesis is the primary driver of neuroprotection in both tauopathy and prion-diseased mice. This is irrespective of sustained high levels of misfolded protein, both prion ([Fig. 3](#awx074-F3){ref-type="fig"}J) and p-tau (in DBM treated mice; [Fig. 4](#awx074-F4){ref-type="fig"}B and E), further demonstrating the central role the UPR plays in neurodegeneration.

In conclusion, we selected trazodone and DBM as potential therapeutic agents in neurodegenerative disease, based on their consistent ability to inhibit UPR/ISR-induced translational repression, rather than target disease-specific misfolded proteins, in organisms ranging from nematodes, through mammalian cell models, to different mouse models of neurodegeneration. The two drugs were markedly neuroprotective in both prion-diseased and FTD mice at clinically relevant doses over a sustained treatment period. These drugs therefore represent an important step forward in the pursuit of disease-modifying treatments for Alzheimer&rsquo;s and related disorders. Trazodone in particular, is already licensed for use in elderly patients. These drugs should now be tested in clinical trials in the treatment of dementia.
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ATF

:   activating transcription factor

CHO

:   Chinese hamster ovary

CHOP

:   C/EBP homologous protein

DBM

:   dibenzoylmethane

eIF2&alpha;

:   eukaryotic initiation factor 2&alpha;

FTD

:   frontotemporal dementia

ISR

:   integrated stress response

PERK

:   pancreatic endoplasmic reticulum kinase

PrP

:   prion protein

UPR

:   unfolded protein response
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[^1]: See Mercado and Hetz (doi:10.1093/brain/awx107) for a scientific commentary on this article.

[^2]: Prion-infected mice were treated daily with trazodone, DBM or vehicle from 7 weeks post-infection, by which stage early neurological prion disease is established and significant synapse loss occurs ([@awx074-B27]). All mice were assessed for appearance of one or more of both early indicator and confirmatory signs of neurological prion disease (&lsquo;scrapie&rsquo;). One confirmatory sign and &gt;2 early indicator signs or two confirmatory signs are required for the diagnosis of clinically definite prion disease. All vehicle-treated animals (*n*&thinsp;&equals;&thinsp;20) had confirmatory signs of terminal prion disease by 83&thinsp;&plusmn;&thinsp;2 days. Only 3/15 trazodone-treated and 6/21 DBM-treated mice developed neurologically definite clinical prion disease (83&thinsp;&plusmn;&thinsp;4 and 84&thinsp;&plusmn;&thinsp;4 days, respectively). The remaining mice showed no confirmatory neurological clinical signs. Other than the occurrence of one or more non-specific early indicator signs, which were mostly transient, they were clinically well.
